SHINE Technologies is partnering with Primo Biotechnology, a developer of high-precision radiopharmaceuticals, the company announced today.

According to a release, the agreement grants Primo exclusive distribution rights for SHINE’s Ilumira in Taiwan and additional sales rights in Japan, South Korea and Singapore.

“This collaboration marks a pivotal step in bringing precision and hope to patients across Asia-Pacific,” Primo Biotechnology CEO Dr. Ya-Yao Huang said in a statement. “By partnering with SHINE, we ensure a stable supply of high-quality isotopes and advance cancer care in the region.”

Under the partnership, Primo will gain priority access to SHINE’s therapeutic isotopes, ensuring a reliable supply for emerging nuclear medicine applications.